Changes in Hong Kong stocks | FuRui Medical Technology (01696) opened more than 4% of long-acting botulinum toxin products Daxifei passed the China Inspection Institute's quality standards

The Zhitong Finance App learned that FuRui Medical Technology (01696) opened more than 4% higher. As of press release, it had risen 4.55% to HK$4.6, with a turnover of HK$38,600.

According to the news, FuRui Medical Technology announced that its long-acting type A botulinum toxin product Daxifil (English trademark DAXXIFY) has officially passed the quality standard inspection by the China Food and Drug Administration Research Institute, indicating that Daxifil has met the strict requirements of the national drug regulatory system in terms of quality, safety and efficacy, and successfully completed the final key step before marketing.

The company believes that Dashfield, as the strategic cornerstone of the company's injection-filling business, will provide beauty seekers with more high-quality choices by enriching the diversity of the company's product portfolio, and will be used as a second growth engine to bring continuous consumables revenue to the company and consolidate the company's leading position in the global beauty and health industry.